Sec Form 4 Filing - Hove Anders D @ Anacor Pharmaceuticals Inc - 2012-09-20

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Hove Anders D
2. Issuer Name and Ticker or Trading Symbol
Anacor Pharmaceuticals Inc [ ANAC]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O VENROCK, 3340 HILLVIEW AVE.
3. Date of Earliest Transaction (MM/DD/YY)
09/20/2012
(Street)
PALO ALTO, CA94304
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/20/2012 S 19,273 D $ 6.3019 3,725,535 I By Funds and LLC's ( 1 ) ( 2 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Hove Anders D
C/O VENROCK
3340 HILLVIEW AVE.
PALO ALTO, CA94304
X X
Signatures
/s/ Anders D. Hove 09/24/2012
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Consists of 1,721,350 shares held by Venrock Associates IV, L.P. ("VA4"), 351,036 shares held by Venrock Partners, L.P. ("VP"), 42,293 shares held by Venrock Entrepreneurs Fund IV, L.P. ("VEF4"), 1,361,755 shares held by Venrock Healthcare Capital Partners, L.P. ("VHCP"), 249,101 shares held by VHCP Co-Investment Holdings LLC ("VHCP Co-Invest"), 0 shares held by Venrock Associates V, L.P. ("VA5"), 0 shares held by Venrock Partners V, L.P. ("VP5"), 0 shares held by Venrock Management IV, LLC ("VM4"), 0 shares held by Venrock Partners Management, LLC ("VPM"), 0 shares held by VEF Managment IV, LLC ("VEFM4") and 0 shares held by VHCP Management, LLC ("VHCP Management").
( 2 )VM4, VPM, VEFM4 are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. Venrock Management V, LLC ("VM5") and Venrock Partners Management V, LLC ("VPM5") are the sole general partners of VA5 and VP5, respectively, and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM, VEFM4, VM5 and VPM5 and a managing member of VHCP Management. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VA5, VP5, VHCP, VHCP Co-Invest, VM4, VPM, VEFM4, VM5, VPM5 and VHCP Management except to the extent of his indirect pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.